New ADA Care Standards in Diabetes; FDA Clears AI-Based Diagnostic; Cannabis and T1D

It’s that time of year again: the American Diabetes Association released its annual Standards of Medical Care in Diabetes, with new updates on managing diabetes and prediabetes. (Diabetes Care)

Although childhood obesity rates were already steadily rising before, the COVID-19 pandemic only seemed to accelerate this trend in Massachusetts. (JAMA Pediatrics)

The FDA cleared Koios Medical’s new artificial intelligence technology that is able to diagnose thyroid and breast cancer in just 2 seconds. (FierceBiotech)

The NIH detailed findings from a study on “responsive parenting” focused on preventing obesity in firstborn children. “The vast majority of parents have multiple children, and so a parenting strategy that can be taught once and then show benefits through subsequent children may be a path forward in helping curb the rising problem of childhood obesity,” said Voula Osganian, MD, ScD, MPH, of the National Institute of Diabetes and Digestive and Kidney Diseases, in a statement.

Consuming more salt was linked with higher levels of fasting plasma glucose and HbA1c in people with type 2 diabetes. (Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)

Cannabis users with type 1 diabetes saw a significantly higher bicarbonate and pH levels — especially 7.4 or higher — when presenting with diabetic ketoacidosis, leading researchers to state in Diabetes Care that cannabis “use should be considered in the differential diagnosis.”

Researchers at the University of Exeter in England are developing a new treatment that targets the brain to help ward off hypoglycemia. (ScienceDaily)

The first participant was dosed in the phase I/II proof-of-concept clinical trial for a novel treatment for thyroid eye disease, Viridian Therapeutics announced.